A comparative study of in vivo mutation assays: analysis of hprt, lacI, and cII/cI as mutational targets for N-nitroso-N-methylurea and benzo[a]pyrene in Big Blue™ mice

We have compared the response of the native hprt gene and the lacI , cII , and cI transgenes in Big Blue™ B6C3F1 mice following treatment with either N -nitroso- N -methylurea (MNU) or benzo[ a ]pyrene (B a P). Three weeks after mutagen treatment splenic T cells were isolated from the animals, and samples were either cultured to measure mutation at the native hprt locus or used to extract genomic DNA for transgene mutation analysis. Phage rescued from extracted DNA were plated in the presence of 5-bromo-4-chloro-3-indolyl-β- d -galactopyranoside (X-gal) to score lacI mutations, or plated on a hflAB lawn to score cII and cI mutants. With MNU hprt mutant frequency increased in a dose-related, sublinear manner up to 78-fold above background at the highest dose tested (20 mg/kg). In comparison, the lacI transgene yielded only a 3.1-fold increase at this dose, and the cII and cI transgenes did not show any increase. With 150 mg/kg B a P a 5.8- and 8.7-fold increase in mutant frequency was observed at hprt and lacI , respectively, while only a 1.3-fold increase was observed at cII . DNA sequencing revealed an increase in GC→TA transversions among the cII mutants, suggesting that the increase was related to B a P exposure. No significant increase in cI mutant frequency was observed. Therefore, the order of mutation assay sensitivity was hprt > lacI > cII/cI with MNU, and hprt ≈ lacI > cII/cI with B a P. While the hflAB selection system offers significant advantages with respect to cost and effort when compared to the lacI assay, additional evaluation of its sensitivity is warranted.